University of Arizona Cancer Center
University of Arizona Cancer Center
Tucson, Arizona, United States13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Digestive System Diseases, Digestive System Neoplasms, Fibrosis, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, epithelial neoplasm, fatty liver disease, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-10-08 | NCT06096779 | |
| DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-10-07 | NCT04567420 | |
| A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-10-06 | NCT06091254 | |
| A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-23 | NCT07063745 | |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-22 | NCT07213674 | |
| GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, hepatocellular carcinoma, intestinal disorder, liver disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder | Recruiting | Early phase 1 | 2026-09-18 | NCT07627191 | |
| Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 2 | 2026-09-11 | NCT04820179 | |
| Adaptive Symptom Self-Management Immunotherapy Study | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast cancer, breast disorder, breast neoplasm, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, lung cancer, lung disorder, lung neoplasm, malignant colon neoplasm, neoplasm, rectal cancer, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm | Active, not recruiting | Not applicable | 2026-07-31 | NCT05715255 | |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-07-02 | NCT06578247 | |
| A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma | HER2/Neu+ Uterine Serous Carcinoma | Recruiting | Phase 2 | 2026-06-22 | NCT02491099 | |
| Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) | Ear Diseases, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Site, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, gonadal disorder, head and neck cancer, hearing disorder, hearing loss disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, nervous system disorder, otorhinolaryngologic disease, testicular cancer, testicular disorder, thoracic cancer | Recruiting | Phase 1 / Phase 2 | 2026-06-18 | NCT07407582 | |
| A Nutrition & Exercise Prehabilitation Intervention on Inflammatory Biomarkers in AI Cancer Patients | cancer, neoplasm | Recruiting | Not applicable | 2026-04-30 | NCT06644560 | |
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Uveal Neoplasms, connective tissue neoplasm, cutaneous melanoma, eye disorder, fibrosarcoma, melanocytic neoplasm, melanoma, mucosal melanoma, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroendocrine neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, ocular cancer, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, sarcoma, skin disorder, skin neoplasm, uveal disorder, uveal melanoma | Active, not recruiting | Phase 1 / Phase 2 | 2025-08-07 | NCT03611868 |